Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)

Next Previous
Trial Profile

A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tildrakizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms reSURFACE 1
  • Sponsors Merck & Co; Sun Pharma Global FZE; Sun Pharmaceutical Industries

    • Most Recent Events

    • 06 Jul 2023 Results of Pooled analysis of 5-year safety data from reSURFACE 1 and reSURFACE 2; published in the Journal of Dermatological Treatment
    • 21 Mar 2023 Results of Pooled analyses from reSURFACE 1 and reSURFACE 2; analyzing efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles, presented at the American Academy of Dermatology annual Meeting 2023
    • 26 Sep 2022 Results of post-hoc analysis of two studies (reSURFACE 1 (NCT01722331) and reSURFACE 2 (NCT01729754) ) assessing tildrakizumab efficacy and safety for up to 5 years in patients with and without metabolic syndrome, published in the Journal of the European Academy of Dermatology and Venereology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top